angiotensin ii has been researched along with oxadiazoles in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 5 (21.74) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Barhanin, J; Frelin, C; Lazdunski, M; Schmid-Alliana, A; Van Renterghem, C; Vigne, P | 1 |
| Swartz, SL | 1 |
| Bulcäo, C; Cunha, M; De Castro-e-Silva, E; De Oliveira, IR; Fregoneze, JB; Luz, CP; Marinho, A; Nascimento, TA; Sarmento, C; Soares, T | 1 |
| Ackermann, A; Fernández-Alfonso, MS; González, C; Ortega, T; Paul, M; Sánchez de Rojas, R | 1 |
| Cohen, RA; Griswold, MC; Komalavilas, P; Lincoln, TM; Weisbrod, RM; Yaghoubi, M | 1 |
| Brown, C; Hassid, A; Pan, X | 1 |
| Carlson, EJ; Drewett, JG; Kreklau, EL | 1 |
| Mayeux, PR; Zhang, C | 1 |
| de Godoy, MA; de Oliveira, AM; Fukada, SY; Tirapelli, CR | 1 |
| Deuchars, J; James, PE; Kasparov, S; Lonergan, T; Paton, JF | 1 |
| Chen, J; Fan, F; Han, L; Wang, S; Wang, X; Xie, X; Yan, J; Zhou, X | 1 |
| Castillo, C; Castillo, EF; López, RM; Pérez, T | 1 |
| Igata, H; Imanishi, M; Kawaguchi, N; Kuroita, T; Kusumoto, K; Nagaya, H; Nishigaki, N; Ojima, M; Sakamoto, H; Tsuboi, A; Yamaguchi, F | 1 |
| Brands, CM; Corral, E; de Roode, DF; Desmares-Koopmans, MJ; Migchielsen, MH; Oudhoff, KA; Weltman, R | 1 |
| Kusumoto, K | 1 |
| Bigler Wang, D; Carlson, JM; Felder, RA; Gildea, JJ; Tran, HT; Van Sciver, RE | 1 |
| Arimoto, M; Hata, H; Osaka, S; Sakino, H; Sezai, A; Shiono, M; Yaoita, H | 1 |
| Côco, H; Cunha, TM; de Oliveira, AM; Gomes, MS; Lopes, AH; Marchi, KC; Pereira, PC; Pernomian, L; Tirapelli, CR | 1 |
| Gao, Q; Jiang, T; Ou, Z; Shi, JQ; Tian, YY; Wu, L; Zhang, YD; Zhou, JS | 1 |
| Hayakawa, Y; Iwasa, M; Kanamori, H; Kawasaki, M; Komaki, H; Minatoguchi, S; Nishigaki, K; Okamoto, C; Yamada, Y | 1 |
| Idemoto, Y; Kitajima, K; Kuwano, T; Matsuo, Y; Miura, SI; Suematsu, Y | 1 |
| Bai, L; Choi, SY; Jeong, MH; Kee, HJ; Kee, SJ; Kim, GR; Kook, H; Seok, YM | 1 |
| Cai, SA; Hou, N; Huang, Y; Li, LR; Liu, XW; Luo, CF; Pan, WB; Shi, YY; Yuan, WC; Zhan, HX; Zhao, GJ | 1 |
1 review(s) available for angiotensin ii and oxadiazoles
| Article | Year |
|---|---|
[In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypertension; Insulin Resistance; Obesity; Oxadiazoles | 2012 |
1 trial(s) available for angiotensin ii and oxadiazoles
| Article | Year |
|---|---|
Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Blood Pressure; Cardiac Surgical Procedures; Drug Substitution; Essential Hypertension; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Japan; Male; Middle Aged; Oxadiazoles; Prospective Studies; Renin; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Ventricular Remodeling | 2016 |
21 other study(ies) available for angiotensin ii and oxadiazoles
| Article | Year |
|---|---|
Molecular mechanism of action of the vasoconstrictor peptide endothelin.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Action Potentials; Angiotensin II; Animals; Aorta, Thoracic; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Membrane; Electrophysiology; Endothelins; Endothelium, Vascular; Inositol 1,4,5-Trisphosphate; Inositol Phosphates; Isradipine; Oxadiazoles; Peptides; Phosphatidylinositols; Rats; Rats, Inbred Strains; Vasoconstriction; Vasopressins | 1988 |
Antihypertensive and hormonal effects of PN 200-110, a new calcium-channel blocker, in essential hypertension.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Calcium Channel Blockers; Dinoprostone; Female; Hormones; Humans; Hypertension; Isradipine; Male; Middle Aged; Oxadiazoles; Prostaglandins E; Renin; Vascular Resistance | 1987 |
Effect of third ventricle administration of L-694,247, a selective 5-HT1D receptor agonist, on water intake in rats.
Topics: Adrenergic beta-Agonists; Angiotensin II; Animals; Carbachol; Drinking; Injections, Intraventricular; Isoproterenol; Male; Microinjections; Muscarinic Agonists; Oxadiazoles; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Tryptamines; Water Deprivation | 1997 |
Modulation of angiotensin-converting enzyme by nitric oxide.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Carotid Arteries; Diethylamines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanylate Cyclase; Male; Molsidomine; Muscle, Smooth, Vascular; Nitric Oxide; Oligopeptides; Oxadiazoles; Peptidyl-Dipeptidase A; Quinoxalines; Rabbits; Rats; Rats, Sprague-Dawley | 1998 |
Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-GMP Phosphodiesterases; Angiotensin II; Animals; Aorta; Calcium; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanylate Cyclase; Manganese; Muscle Relaxation; Muscle, Smooth; Nitric Oxide; Oxadiazoles; Phosphodiesterase Inhibitors; Protein Kinase C; Purinones; Quinoxalines; Rabbits; Thionucleotides; Vasoconstrictor Agents; Vasodilator Agents | 1998 |
Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: relationship to microfilament dissociation and altered cell morphology.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Actin Cytoskeleton; Angiotensin II; Animals; Aorta, Thoracic; Cell Movement; Cells, Cultured; Culture Media; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cytoskeleton; Diffusion Chambers, Culture; Guanylate Cyclase; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Myosin Heavy Chains; Natriuretic Peptide, C-Type; Nitric Oxide; Nitric Oxide Donors; Oxadiazoles; Penicillamine; Quinoxalines; Rats; Rats, Sprague-Dawley | 1999 |
Nitric oxide inhibits human aldosteronogenesis without guanylyl cyclase stimulation.
Topics: Adrenal Cortex; Aldosterone; Angiotensin II; Animals; Cell Line; Colforsin; Cyclic GMP; Enzyme Inhibitors; Guanylate Cyclase; Humans; Hydroxycholesterols; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Nitroso Compounds; Oxadiazoles; PC12 Cells; Quinoxalines; Rats | 1999 |
NO/cGMP signaling modulates regulation of Na+-K+-ATPase activity by angiotensin II in rat proximal tubules.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine; Calcium; Cyclic GMP; Enzyme Inhibitors; Guanylate Cyclase; Intracellular Membranes; Kidney Tubules, Proximal; Male; Nitric Oxide; omega-N-Methylarginine; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Signal Transduction; Sodium-Potassium-Exchanging ATPase; Solubility | 2001 |
Analysis of the mechanisms underlying the vasorelaxant action of angiotensin II in the isolated rat carotid.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Arteries; Dose-Response Relationship, Drug; Drug Antagonism; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Oxadiazoles; Peptide Fragments; Phenylephrine; Quinoxalines; Rats; Rats, Wistar; Saralasin; Vasoconstrictor Agents; Vasodilation | 2006 |
Detection of angiotensin II mediated nitric oxide release within the nucleus of the solitary tract using electron-paramagnetic resonance (EPR) spectroscopy.
Topics: Angiotensin II; Animals; Baroreflex; Drug Interactions; Electron Spin Resonance Spectroscopy; Guanylate Cyclase; Hydrazines; Immunohistochemistry; In Vitro Techniques; Male; Microscopy, Immunoelectron; Nitric Oxide; Nitric Oxide Donors; Nitrogen Oxides; Oxadiazoles; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Solitary Nucleus | 2006 |
Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Cardiovascular Agents; Cell Proliferation; Cell Size; Cells, Cultured; Cyclic GMP; Fibroblasts; Intracellular Space; L-Lactate Dehydrogenase; Male; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Resveratrol; Signal Transduction; Stilbenes | 2007 |
Effects induced by inhibitors of the phosphatidylinositol 3-kinase/Akt and nitric oxide synthase/guanylyl cyclase pathways on the isometric contraction in rat aorta: a comparative study.
Topics: Androstadienes; Angiotensin II; Animals; Aorta, Thoracic; Chromones; Endothelium, Vascular; Guanylate Cyclase; Isometric Contraction; Male; Morpholines; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Oxadiazoles; Phenylephrine; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Potassium; Proto-Oncogene Proteins c-akt; Quinoxalines; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; Wortmannin | 2011 |
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Blood Glucose; Blood Pressure; CHO Cells; Cricetinae; Cricetulus; Dogs; Hypertension; Hypertension, Renal; Imidazoles; Insulin; Male; Olmesartan Medoxomil; Oxadiazoles; Protective Agents; Proteinuria; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Tetrazoles | 2011 |
Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.
Topics: Adsorption; Angiotensin II; Animals; Bacteria; Benzimidazoles; Biodegradation, Environmental; Daphnia; Environmental Monitoring; Geologic Sediments; Microalgae; Octanols; Oxadiazoles; Risk Assessment; Sewage; Toxicity Tests; Water Pollutants, Chemical | 2012 |
A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells.
Topics: Angiotensin II; Cell Line; Cells, Cultured; G-Protein-Coupled Receptor Kinase 4; Humans; Kidney Tubules, Proximal; Losartan; Oxadiazoles; Phorbol Esters; Proto-Oncogene Proteins c-myc; Receptor, Angiotensin, Type 1; Receptors, Dopamine; Transcription, Genetic | 2013 |
Chronic restraint stress increases angiotensin II potency in the rat carotid: role of cyclooxygenases and reactive oxygen species.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Carotid Arteries; Catalase; Corticosterone; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Endothelium, Vascular; Hydrogen Peroxide; Male; Muscle Contraction; Muscle, Smooth, Vascular; NADPH Oxidase 4; NADPH Oxidases; Oxadiazoles; Phosphatidylinositol 3-Kinases; Prostaglandin-Endoperoxide Synthases; Proto-Oncogene Proteins c-akt; Rats, Wistar; Reactive Oxygen Species; Restraint, Physical; Stress, Psychological; Vasoconstriction | 2017 |
Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic parkinsonian behaviors in a rat model of Parkinson's disease.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Behavior, Animal; Benzimidazoles; Disease Models, Animal; Dopaminergic Neurons; Humans; Male; Oxadiazoles; Parkinson Disease; Rats; Receptor, Angiotensin, Type 1; Substantia Nigra | 2017 |
Azilsartan attenuates cardiac damage caused by high salt intake through the downregulation of the cardiac (pro)renin receptor and its downstream signals in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Blood Pressure; Down-Regulation; Heart; Hypertension; Myocardium; Oxadiazoles; Phosphorylation; Prorenin Receptor; Rats; Rats, Inbred SHR; Receptors, Cell Surface; Signal Transduction; Sodium Chloride, Dietary; Transforming Growth Factor beta1 | 2018 |
Changes in the function of angiotensin II type 1 receptor due to cholesterol depletion from cell membrane.
Topics: Angiotensin II; Animals; Benzimidazoles; Cell Membrane; Chlorocebus aethiops; Cholesterol; COS Cells; Cyclic AMP; HEK293 Cells; Humans; Inositol Phosphates; Myocytes, Cardiac; Myocytes, Smooth Muscle; Oxadiazoles; Rats; Receptor, Angiotensin, Type 1 | 2019 |
HDAC5 inhibition reduces angiotensin II-induced vascular contraction, hypertrophy, and oxidative stress in a mouse model.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Arterial Pressure; Benzamides; Cells, Cultured; Disease Models, Animal; Histone Deacetylase Inhibitors; Histone Deacetylases; Hypertension; Male; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxadiazoles; Oxidative Stress; rho-Associated Kinases; rhoA GTP-Binding Protein; Vascular Remodeling; Vasoconstriction | 2021 |
Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antioxidants; Benzimidazoles; Cardiomegaly; Female; Heart Ventricles; Kelch-Like ECH-Associated Protein 1; Male; Myocardium; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxadiazoles; Oxidative Stress; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Up-Regulation | 2021 |